Match!
Aysegul Karaman
Dokuz Eylül University
ImatinibTyrosine-kinase inhibitorHastaCancer researchMedicine
2Publications
1H-index
2Citations
What is this?
Publications 2
Newest
#1Aysegul KaramanH-Index: 1
Last. Mehmet Ali ÖzcanH-Index: 15
view all 12 authors...
Amac: Kronik Miyeloid Losemi (KML) pluripotent kok hucrelerin anormal cogalmasi ile olusan miyeloproliferatif bir hastaliktir ve eriskin losemilerinin %15’ini olusturur. Tirozin kinaz inhibitorleri (TKI) KML’nin ana tedavisi haline gelmistir. Yeni kusak TKI’lerinin kullanimi ile direncli vakalarda etkin tedavi saglanmistir. Calismamizda KML tanili hastalarin retrospektif olarak verilerini inceleyerek literature katki amacli sunmayi planladik. Gerec ve yontem: Calismamiza 2003 –2014 tarihleri ara...
#1Fatih Demirkan (Dokuz Eylül University)H-Index: 13
#2Omur Gokmen Sevindik (Dokuz Eylül University)H-Index: 3
Last. Güner Hayri Özsan (Dokuz Eylül University)H-Index: 6
view all 6 authors...
e18024 Background: Tyrosine kinase inhibitors are the mainstay of treatment of chronic myeloid leukemia (CML). Recently, four different generic Imatinib formulations were approved for the frontline...
2 CitationsSource
1